Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Viruses ; 9(10)2017 10 20.
Article in English | MEDLINE | ID: mdl-29053589

ABSTRACT

Programmed cell death or apoptosis is an important component of host defense systems against viral infection. The B-cell lymphoma 2 (Bcl-2) proteins family is the main arbiter of mitochondrially mediated apoptosis, and viruses have evolved sequence and structural mimics of Bcl-2 to subvert premature host cell apoptosis in response to viral infection. The sequencing of the canarypox virus genome identified a putative pro-survival Bcl-2 protein, CNP058. However, a role in apoptosis inhibition for CNP058 has not been identified to date. Here, we report that CNP058 is able to bind several host cell pro-death Bcl-2 proteins, including Bak and Bax, as well as several BH3 only-proteins including Bim, Bid, Bmf, Noxa, Puma, and Hrk with high to moderate affinities. We then defined the structural basis for CNP058 binding to pro-death Bcl-2 proteins by determining the crystal structure of CNP058 bound to Bim BH3. CNP058 adopts the conserved Bcl-2 like fold observed in cellular pro-survival Bcl-2 proteins, and utilizes the canonical ligand binding groove to bind Bim BH3. We then demonstrate that CNP058 is a potent inhibitor of ultraviolet (UV) induced apoptosis in a cell culture model. Our findings suggest that CNP058 is a potent inhibitor of apoptosis that is able to bind to BH3 domain peptides from a broad range of pro-death Bcl-2 proteins, and may play a key role in countering premature host apoptosis.


Subject(s)
Apoptosis Regulatory Proteins/metabolism , Apoptosis , Canarypox virus/physiology , Viral Proteins/chemistry , Viral Proteins/metabolism , Apoptosis/radiation effects , Apoptosis Regulatory Proteins/chemistry , Apoptosis Regulatory Proteins/genetics , Bcl-2-Like Protein 11/chemistry , Bcl-2-Like Protein 11/metabolism , Calorimetry , Canarypox virus/chemistry , Canarypox virus/genetics , Crystallography, X-Ray , Gene Expression Regulation , Genome, Viral , Humans , Protein Binding , Protein Conformation , Protein Domains , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Ultraviolet Rays , Viral Proteins/genetics
2.
J Zoo Wildl Med ; 45(2): 315-20, 2014 Jun.
Article in English | MEDLINE | ID: mdl-25000692

ABSTRACT

Captive Eld's deer (Rucervus eldi thamin) were evaluated for the presence of rabies virus-neutralizing antibodies using a rapid fluorescent focus inhibition after vaccination with either a live canarypox-vectored recombinant rabies vaccine or a killed monovalent rabies vaccine. Twelve deer were vaccinated with 1.0 ml of killed, adjuvanted, monovalent rabies vaccine at 5-33 mo of age then annually thereafter, and 14 deer were vaccinated with 1.0 ml nonadjuvanted, live canarypox-vectored rabies vaccine at 3-15 mo of age then annually thereafter. Banked serum was available or collected prospectively from deer at 6 mo and 1 yr after initial vaccination, then collected annually. Rabies virus-neutralizing antibodies considered adequate (>0.5 IU/ml) were present in 20/34 samples vaccinated with canarypox-vectored rabies vaccine and in 12/14 samples vaccinated with killed adjuvanted rabies vaccine. Poor seroconversion was noted in deer less than 6 mo of age vaccinated with the canarypox-vectored rabies vaccine.


Subject(s)
Antibodies, Viral/blood , Canarypox virus/physiology , Deer/blood , Rabies Vaccines/immunology , Rabies/veterinary , Adjuvants, Immunologic , Animals , Female , Genetic Vectors , Male , Prospective Studies , Rabies/prevention & control , Rabies virus/genetics , Rabies virus/immunology , Recombinant Proteins , Vaccination/methods , Vaccines, Synthetic/genetics , Viral Proteins
3.
Antiviral Res ; 88(1): 53-63, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20643163

ABSTRACT

Canarypox and fowlpox viruses represent alternative vaccine vectors due to their natural host-range restriction to avian species. Although they cannot replicate in mammals, they correctly express transgenes in human cells and elicit a complete immune response in vaccinated subjects. Several studies have evaluated their genomic differences and protective efficacy in preclinical trials, but detailed information is not available for their transgene expression, cytokine modulation and abortive replication in mammals. This study demonstrates that the heterologous HIV gag/pol and env genes are more efficiently expressed by fowlpox in non-immune and immune cells. The production of retrovirus-like particles, the longer transgene expression, and a balanced cytokine induction may confer to fowlpox-based recombinants the ability to elicit a better immune response.


Subject(s)
AIDS Vaccines , Canarypox virus , Fowlpox virus , Genetic Vectors , HIV-1/genetics , Vaccines, Synthetic , AIDS Vaccines/genetics , AIDS Vaccines/immunology , Animals , B7-1 Antigen/analysis , Canarypox virus/genetics , Canarypox virus/immunology , Canarypox virus/physiology , Canarypox virus/ultrastructure , Cell Line , Cytokines/immunology , Dendritic Cells/immunology , Fluorescent Antibody Technique , Fowlpox virus/genetics , Fowlpox virus/immunology , Fowlpox virus/physiology , Fowlpox virus/ultrastructure , Gene Expression , Genes, env , Genes, gag , Genes, pol , HIV-1/immunology , Humans , Immunization , Macrophages/immunology , Microscopy, Electron, Transmission , Transgenes , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Virus Replication/genetics
4.
Arch Virol ; 155(6): 915-24, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20379750

ABSTRACT

Due to their natural host-range restriction to avian species, canarypox virus (CP) and fowlpox virus (FP) represent efficient and safe vaccine vectors, as they correctly express transgenes in human cells, elicit complete immune responses, and show protective efficacy in preclinical animal models. At present, no information is available on the differences in the abortive replication of these two avipox viruses in mammalian cells. In the present study, the replicative cycles of CP and FP, wild-type and recombinants, are compared in permissive and non-permissive cells, using transmission electron microscopy. We demonstrate that in non-permissive cells, the replicative cycle is more advanced in FP than in CP, that human cells, whether immune or not, are less permissive to avipox replication than monkey cells, and that the presence of virus-like particles only occurs after FP infection. Overall, these data suggest that the use of FP recombinants is more appropriate than the use of CP for eliciting an immune response.


Subject(s)
Canarypox virus/ultrastructure , Fowlpox virus/ultrastructure , Genetic Vectors , Vaccines, Synthetic , Animals , Canarypox virus/genetics , Canarypox virus/immunology , Canarypox virus/physiology , Cell Line , Fowlpox virus/genetics , Fowlpox virus/immunology , Fowlpox virus/physiology , Genetic Vectors/genetics , Genetic Vectors/immunology , Genetic Vectors/physiology , Genetic Vectors/ultrastructure , Humans , Microscopy, Electron, Transmission , Transgenes/physiology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/ultrastructure , Virion/physiology , Virion/ultrastructure , Virus Replication
5.
Vaccine ; 24(40-41): 6376-91, 2006 Sep 29.
Article in English | MEDLINE | ID: mdl-16859816

ABSTRACT

The poxviruses including canarypox (ALVAC) and vaccinia viruses are promising vaccine vectors in humans, but little is known about their biology in human cells. Using recombinant enhanced green fluorescence protein (EGFP)-expressing ALVAC and vaccinia viruses, we have focused here on a side-by-side comparison of ALVAC and vaccinia virus tropism for cells from human peripheral blood and bone marrow. Both ALVAC and vaccinia viruses showed a strong bias towards monocyte infection. ALVAC minimally infected CD19+ B cells and was unable to infect ex vivo NK cells and T lymphocytes, whereas vaccinia virus could infect B lymphocytes and NK cell populations. Vaccinia virus was also able to infect T lymphocytes at low, but detectable levels that could be enhanced upon their activation. The observed preferential infection of ALVAC or vaccinia virus to monocytes was the result of preferential binding to this population, rather than lineage-specific differences in the expression of viral genes. Moreover, the level of CD14 expression on monocytes correlated with their preference to be infected with ALVAC or vaccinia virus. Both ALVAC and vaccinia viruses could infect immature monocyte derived dendritic cells (MDDCs), but only ALVAC infection induced their subsequent maturation. Vaccinia virus, however, showed greater tropism for mature MDDCs compared to ALVAC. Infection in human bone marrow cultures showed that ALVAC infection was restricted to a myelomonocytoid cell-specific CD33(+) cell population, while vaccinia virus showed a strong, but not exclusive, preference for these cells. These findings have implications in terms of choosing optimal pox virus derived vectors as vaccines in terms of reducing clinical reactogenicity and inducing dendritic cell (DC) maturation.


Subject(s)
Canarypox virus/physiology , Cell Lineage , Monocytes/cytology , Monocytes/virology , Vaccinia virus/physiology , CD40 Ligand/metabolism , Canarypox virus/genetics , Cells, Cultured , Dendritic Cells/cytology , Dendritic Cells/virology , Humans , Lipopolysaccharide Receptors/metabolism , Time Factors , Vaccinia virus/genetics
6.
AIDS Res Hum Retroviruses ; 20(8): 871-84, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15320991

ABSTRACT

Dendritic cells (DCs) infected with recombinant avipox vectors express the introduced genes and activate antigen-specific T cells. DCs exhibit distinct differentiation-dependent immune functions. Moreover, immature DCs are readily infected by canarypox vectors, but undergo tumor necrosis factor (TNF)-alpha-dependent death, while fewer mature DCs get infected and resist dying. A pilot study was performed using the rhesus macaque system to explore whether immature and mature DCs infected with SIV-recombinant canarypox (vCP180) ex vivo could induce primary virus-specific immune responses in vivo. After subcutaneous (sc) reinjection, functional monocyte-derived DCs migrated to lymph nodes (LNs) within 1-2 days and primed T cells in vivo. This was observed by monitoring dye-labeled DCs in the draining LNs and tetanus toxoid (TT)-specific T cell responses after injection of TT-loaded DCs. DCs from simian immunodeficiency virus (SIV)-naïve rhesus macaques were infected with vCP180 (SIVmac142 gag, pol, and env genes), and sc reinjected into donor animals. Low-level SIV-specific T cell proliferation, but little if any interferon (IFN)-gamma production was detected. DCs pulsed with vCP180 in combination with TT and keyhole limpet hemocyanin (KLH) (to activate additional T cells and provide "helper" cytokines) induced SIV-, TT-, and KLH-specific T cell responses, including IFN-gamma responses not seen when vCP180-carrying DCs were used alone. Interleukin (IL)-10 and low-level antibody responses were also observed. This pilot study provides the proof of principle that sc injected ex vivo SIV-recombinant canarypox-infected DCs safely induce low-level SIV-specific immune responses in vivo.


Subject(s)
Canarypox virus/immunology , Dendritic Cells/virology , Simian Immunodeficiency Virus/immunology , Animals , Canarypox virus/genetics , Canarypox virus/physiology , Dendritic Cells/immunology , Genetic Vectors , Macaca mulatta , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/physiology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/physiology , Vaccines, Synthetic
7.
Clin Cancer Res ; 9(12): 4347-55, 2003 Oct 01.
Article in English | MEDLINE | ID: mdl-14555505

ABSTRACT

PURPOSE: The therapeutic effectiveness of cancer vaccines, composed of tumor antigens that are also self-antigens, may be limited by the normal mechanisms that preserve immunological tolerance. Consistent with this notion, we found that vaccination of melanoma patients with recombinant viral vaccines expressing gp100 (a melanoma antigen also expressed by normal melanocytes) produced only transient increases in noncytotoxic T cells specific for immunodominant gp100 epitopes. To improve the therapeutic effects of these vaccines, IFN-alpha2b (IFN-alpha) was administered to some high-risk patients. EXPERIMENTAL DESIGN: 7 HLA-A*0201(+) patients were injected with high doses of IFN-alpha (20 MU/m(2) x 20 doses) at various times after completing the vaccination protocol. Clinical toxicity and responses were documented, and the effects on gp100-reactive T cells were measured by IFN-gamma enzyme-linked immunospot assays, tetramers of HLA-A*0201 and gp100 epitopes, and cellular cytotoxicity assays. RESULTS: In patients who had previously responded to vaccination, high doses of IFN-alpha recalled gp100-reactive T cells with the ability to kill gp100-expressing tumor targets in vitro. Concomitant with the reappearance of these cytotoxic T cells, tumor regression was observed in the two patients with clinically evident metastatic disease. CONCLUSIONS: The finding that high-dose IFN recalls previously activated tumor-reactive T cells with potent killing ability suggests a strategy to maintain antitumor responses initiated by cancer vaccines.


Subject(s)
Antineoplastic Agents/administration & dosage , Canarypox virus/physiology , Cancer Vaccines/administration & dosage , Interferon-alpha/administration & dosage , Melanoma/immunology , Membrane Glycoproteins/immunology , Neoplasm Proteins/immunology , T-Lymphocytes/immunology , Adult , Cell Division , Cytotoxicity, Immunologic , Enzyme-Linked Immunosorbent Assay , Female , HLA-A Antigens/metabolism , HLA-A2 Antigen , Humans , Interferon alpha-2 , Lymphatic Metastasis , Male , Melanocytes/immunology , Melanocytes/pathology , Melanoma/secondary , Melanoma/therapy , Membrane Glycoproteins/genetics , Middle Aged , Neoplasm Proteins/genetics , Recombinant Proteins , Vaccination , gp100 Melanoma Antigen
SELECTION OF CITATIONS
SEARCH DETAIL
...